中国合理用药探索2026，Vol.23Issue(5)：19-23,5.DOI:10.3969/j.issn.2096-3327.2026.05.002
重症肌无力多病共存患者高风险药物识别与靶向治疗进展
High-Risk Drug Identification and Targeted Therapy Progress in Patients with Myasthenia Gravis Complicated with Multiple Diseases
摘要
Abstract
Myasthenia gravis(MG)is an autoimmune disease mediated by autoantibodies and involved in neuromuscular junction(NMJ)transmission.Elderly MG patients are often complicated with multiple diseases,bringing severe challenges to clinical polypharmacy management.Starting with the medication risks of one elderly MG patient with multimorbidity,this article systematically summarizes the identification of high-risk drugs and related medication suggestions for MG patients with multiple diseases,and analyzes the combined medication risks of traditional MG drugs such as cholinesterase inhibitors,glucocorticoids and immunosuppressants.In view of the clinical dilemma of insufficient specificity and high combined medication risk of traditional MG regimens,this paper further expounds the mechanism of action,applicable population,administration route,safety characteristics and drug interaction of three targeted biological agents including efgartigimod,eculizumab and telitacicept,so as to achieve the dual goals of stable disease control and medication safety,and improve the long-term quality of life of patients.关键词
重症肌无力/多病共存/多重用药/用药风险/靶向生物制剂Key words
myasthenia gravis/multiple diseases/polypharmacy/medication risk/targeted biological agents分类
医药卫生引用本文复制引用
杨玉娇,张涵煦,陈丽婷,易湛苗..重症肌无力多病共存患者高风险药物识别与靶向治疗进展[J].中国合理用药探索,2026,23(5):19-23,5.基金项目
北京慢性病防治与健康教育研究会、中关村人才协会医工领域"未来人才"培养计划(MBRC0012025062) （MBRC0012025062）
